Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 13;39(1):66.
doi: 10.1007/s10822-025-00646-9.

Combined experimental and computational investigation of vildagliptin: spectroscopy, electronic structure, MD and Docking to EGFR, VEGFR2, and HER2 anticancer targets

Affiliations

Combined experimental and computational investigation of vildagliptin: spectroscopy, electronic structure, MD and Docking to EGFR, VEGFR2, and HER2 anticancer targets

Tadeusz W Inglot. J Comput Aided Mol Des. .

Abstract

This study combines experimental and computational approaches to investigate the molecular geometry and physicochemical properties of vildagliptin (VILD). Using methods such as UV-Vis, spectrofluorimetry, FTIR/Raman, and circular dichroism alongside DFT, molecular docking, and dynamics simulations, a reliable molecular model was obtained that aligns closely with X-ray crystallographic data. This model enabled accurate predictions of vibrational frequencies and systematic assignments of vibrational modes. Analyses, including Hirshfeld surface mapping, molecular electrostatic potential, HOMO-LUMO energetics, Fukui indices, and natural population analysis, provided clear insights into VILD's reactivity, while NBO and TD-DFT studies elucidated key stabilizing interactions and high-energy electronic transitions. NTO visualization further clarified orbital dynamics, and circular dichroism measurements explained the molecular basis of the Cotton effect. Additionally, molecular docking and molecular dynamics simulations confirmed the formation of stable complexes with EGFR, VEGFR2, and HER2 receptor proteins, suggesting potential anticancer activity. The main purpose of this publication is to fill existing gaps in our understanding of VILD's molecular behavior and offer a robust foundation for rational drug design and improved therapeutic strategies.

Keywords: DFT; FTIR; Raman; Spectroscopy; Vildagliptin.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The author declare no competing interests.

Figures

Fig. 1
Fig. 1
Optimized structure of vildagliptin and atom numbering
Fig. 2
Fig. 2
Experimental A and theoretical, B FTIR spectra of vildagliptin
Fig. 3
Fig. 3
Experimental A and theoretical, B Raman spectra of vildagliptin
Fig. 4
Fig. 4
Hirshfeld surface of VILD mapped over dnorm
Fig. 5
Fig. 5
2D finger plot graphs representing the number of molecular interactions of VILD. A– O H interactions, B– H–H interactions, C– N–H interactions, D– C–H interactions
Fig. 6
Fig. 6
Molecular electrostatic potential surface (MEP) of vildagliptin
Fig. 7
Fig. 7
Frontier molecular orbitals of VILD calculated with DFT
Fig. 8
Fig. 8
Experimental and theoretical UV-Vis spectra of vildagliptin solution in methanol
Fig. 9
Fig. 9
Representation of natural transition orbitals (NTO) of the “particle” and “hole” pairs for the VILD excitations
Fig. 10
Fig. 10
Density of state spectrum of VILD
Fig. 11
Fig. 11
Experimental and theoretical circular dichroism spectra of VILD
Fig. 12
Fig. 12
3D fluorimetric spectrum of vildagliptin solution in methanol
Fig. 13
Fig. 13
Entropy, enthalpy and heat capacity curves calculated for vildagliptin
Fig. 14
Fig. 14
Docking results of VILD and three analyzed proteins with specified, nearest amino acids interacting with the ligand
Fig. 15
Fig. 15
RMSD, RMSF curves, radius of gyration and a number of hydrogen bonds formed between VILD and three analyzed proteins
Fig. 16
Fig. 16
The occupancy plot of the amino acid residues of proteins in contact with VILD (the number of simulation frames from the last 50 ns of MD production run)
Fig. 17
Fig. 17
Binding energies with energy components of VILD complexes with 1M17, 4AG8 and 3PP0 proteins

Similar articles

References

    1. Makrilakis K (2019) The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect. Int J Environ Res Public Health 16:2720. 10.3390/ijerph16152720 - PMC - PubMed
    1. Koliaki C, Doupis J (2011) Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Therapy 2:101–121. 10.1007/s13300-011-0002-3 - PMC - PubMed
    1. Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH (2021) SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 398:262–276. 10.1016/S0140-6736(21)00536-5 - PubMed
    1. Knapen LM, de Jong RGPJ, Driessen JHM, Keulemans YC, van Erp NP, De Bruin ML, Leufkens HGM, Croes S, de Vries F (2017) Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study. Diabetes Obes Metab 19:401–411. 10.1111/dom.12833 - PubMed
    1. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C (2014) Pancreatic safety of Incretin-Based Drugs — FDA and EMA assessment. N Engl J Med 370:794–797. 10.1056/NEJMp1314078 - PubMed

MeSH terms

LinkOut - more resources